Improved Outcomes in High-Risk Smoldering Myeloma: I-PRISM Phase II Trial Results
Key Findings
The I-PRISM phase II clinical trial studied the effects of ixazomib, lenalidomide, and dexamethasone on 55 patients with high-risk smoldering multiple myeloma (HR-SMM). Here are the main results:
- Progression-Free Survival (PFS): The median PFS was not reached after 50 months of follow-up.
- Biochemical PFS: Patients experienced a biochemical PFS of 48.6 months.
- Overall Response Rate: 93% of patients responded to treatment, with 31% achieving a complete response.
- MRD-Negativity: Patients who were minimal residual disease (MRD)-negative had a 100% biochemical PFS at 5 years, compared to 40% for MRD-positive patients.
Practical Solutions and Value
Clinical trials like I-PRISM are essential for developing effective treatments. To make these benefits available in everyday practice, we offer:
- DocSym Platform: An AI-driven tool that combines ICD-11 standards, clinical protocols, and research into one easy-to-use resource for healthcare providers.
- Mobile Apps: Tools that facilitate scheduling, treatment monitoring, and telemedicine, improving patient care management.
- AI Integration: By utilizing AI, clinics can streamline their operations, enhance workflows, and reduce paperwork, ultimately improving patient outcomes.
Discover how we can assist your practice at aidevmd.com.
